Inhibition of hepatitis C virus replication by arsenic trioxide

Der Ren Hwang, Yuan Chin Tsai, Jin Ching Lee, Kuo Kuei Huang, Ren Kuo Lin, Chia Hua Ho, Jeng Min Chiou, Ying Ting Lin, John T A Hsu, Chau Ting Yeh

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) is a serious global problem, and present therapeutics are inadequate to cure HCV infection. In the present study, various antiviral assays show that AS2O3 at submicromolar concentrations is capable of inhibiting HCV replication. The 50% effective concentration (EC50) of AS2O3 required to inhibit HCV replication was 0.35 μM when it was determined by a reporter-based HCV replication assay, and the EC50 was below 0.2 μM when it was determined by quantitative reverse transcription-PCR analysis. As2O3 did not cause cellular toxicity at this concentration, as revealed by an MTS [3-(4,5-dimethylthiozol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] assay. A combination of AS2O3 and alpha interferon exerted synergistic effects against HCV, as revealed by a multiple linear logistic model and isobologram analysis. Furthermore, in an alternative HCV antiviral system that may recapitulate additional steps involved in HCV infection and replication, AS2O3 at 0.3 μM totally abolished the HCV signal, whereas alpha interferon at a high dose (5,000 IU/ml) only partially suppressed the HCV signal. The study highlights the indications for use of a novel class of anti-HCV agent. Further elucidation of the exact antiviral mechanism of AS2O3 may lead to the development of agents with potent activities against HCV or related viruses.

Original languageEnglish
Pages (from-to)2876-2882
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume48
Issue number8
DOIs
Publication statusPublished - Aug 2004
Externally publishedYes

Fingerprint

Virus Replication
Hepacivirus
Antiviral Agents
Virus Diseases
Interferon-alpha
arsenic trioxide
Tetrazolium Salts
Reverse Transcription
Linear Models
Logistic Models
Viruses
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Hwang, D. R., Tsai, Y. C., Lee, J. C., Huang, K. K., Lin, R. K., Ho, C. H., ... Yeh, C. T. (2004). Inhibition of hepatitis C virus replication by arsenic trioxide. Antimicrobial Agents and Chemotherapy, 48(8), 2876-2882. https://doi.org/10.1128/AAC.48.8.2876-2882.2004

Inhibition of hepatitis C virus replication by arsenic trioxide. / Hwang, Der Ren; Tsai, Yuan Chin; Lee, Jin Ching; Huang, Kuo Kuei; Lin, Ren Kuo; Ho, Chia Hua; Chiou, Jeng Min; Lin, Ying Ting; Hsu, John T A; Yeh, Chau Ting.

In: Antimicrobial Agents and Chemotherapy, Vol. 48, No. 8, 08.2004, p. 2876-2882.

Research output: Contribution to journalArticle

Hwang, DR, Tsai, YC, Lee, JC, Huang, KK, Lin, RK, Ho, CH, Chiou, JM, Lin, YT, Hsu, JTA & Yeh, CT 2004, 'Inhibition of hepatitis C virus replication by arsenic trioxide', Antimicrobial Agents and Chemotherapy, vol. 48, no. 8, pp. 2876-2882. https://doi.org/10.1128/AAC.48.8.2876-2882.2004
Hwang, Der Ren ; Tsai, Yuan Chin ; Lee, Jin Ching ; Huang, Kuo Kuei ; Lin, Ren Kuo ; Ho, Chia Hua ; Chiou, Jeng Min ; Lin, Ying Ting ; Hsu, John T A ; Yeh, Chau Ting. / Inhibition of hepatitis C virus replication by arsenic trioxide. In: Antimicrobial Agents and Chemotherapy. 2004 ; Vol. 48, No. 8. pp. 2876-2882.
@article{89cc47d6916e430f9f59a08f117621e9,
title = "Inhibition of hepatitis C virus replication by arsenic trioxide",
abstract = "Hepatitis C virus (HCV) is a serious global problem, and present therapeutics are inadequate to cure HCV infection. In the present study, various antiviral assays show that AS2O3 at submicromolar concentrations is capable of inhibiting HCV replication. The 50{\%} effective concentration (EC50) of AS2O3 required to inhibit HCV replication was 0.35 μM when it was determined by a reporter-based HCV replication assay, and the EC50 was below 0.2 μM when it was determined by quantitative reverse transcription-PCR analysis. As2O3 did not cause cellular toxicity at this concentration, as revealed by an MTS [3-(4,5-dimethylthiozol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] assay. A combination of AS2O3 and alpha interferon exerted synergistic effects against HCV, as revealed by a multiple linear logistic model and isobologram analysis. Furthermore, in an alternative HCV antiviral system that may recapitulate additional steps involved in HCV infection and replication, AS2O3 at 0.3 μM totally abolished the HCV signal, whereas alpha interferon at a high dose (5,000 IU/ml) only partially suppressed the HCV signal. The study highlights the indications for use of a novel class of anti-HCV agent. Further elucidation of the exact antiviral mechanism of AS2O3 may lead to the development of agents with potent activities against HCV or related viruses.",
author = "Hwang, {Der Ren} and Tsai, {Yuan Chin} and Lee, {Jin Ching} and Huang, {Kuo Kuei} and Lin, {Ren Kuo} and Ho, {Chia Hua} and Chiou, {Jeng Min} and Lin, {Ying Ting} and Hsu, {John T A} and Yeh, {Chau Ting}",
year = "2004",
month = "8",
doi = "10.1128/AAC.48.8.2876-2882.2004",
language = "English",
volume = "48",
pages = "2876--2882",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Inhibition of hepatitis C virus replication by arsenic trioxide

AU - Hwang, Der Ren

AU - Tsai, Yuan Chin

AU - Lee, Jin Ching

AU - Huang, Kuo Kuei

AU - Lin, Ren Kuo

AU - Ho, Chia Hua

AU - Chiou, Jeng Min

AU - Lin, Ying Ting

AU - Hsu, John T A

AU - Yeh, Chau Ting

PY - 2004/8

Y1 - 2004/8

N2 - Hepatitis C virus (HCV) is a serious global problem, and present therapeutics are inadequate to cure HCV infection. In the present study, various antiviral assays show that AS2O3 at submicromolar concentrations is capable of inhibiting HCV replication. The 50% effective concentration (EC50) of AS2O3 required to inhibit HCV replication was 0.35 μM when it was determined by a reporter-based HCV replication assay, and the EC50 was below 0.2 μM when it was determined by quantitative reverse transcription-PCR analysis. As2O3 did not cause cellular toxicity at this concentration, as revealed by an MTS [3-(4,5-dimethylthiozol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] assay. A combination of AS2O3 and alpha interferon exerted synergistic effects against HCV, as revealed by a multiple linear logistic model and isobologram analysis. Furthermore, in an alternative HCV antiviral system that may recapitulate additional steps involved in HCV infection and replication, AS2O3 at 0.3 μM totally abolished the HCV signal, whereas alpha interferon at a high dose (5,000 IU/ml) only partially suppressed the HCV signal. The study highlights the indications for use of a novel class of anti-HCV agent. Further elucidation of the exact antiviral mechanism of AS2O3 may lead to the development of agents with potent activities against HCV or related viruses.

AB - Hepatitis C virus (HCV) is a serious global problem, and present therapeutics are inadequate to cure HCV infection. In the present study, various antiviral assays show that AS2O3 at submicromolar concentrations is capable of inhibiting HCV replication. The 50% effective concentration (EC50) of AS2O3 required to inhibit HCV replication was 0.35 μM when it was determined by a reporter-based HCV replication assay, and the EC50 was below 0.2 μM when it was determined by quantitative reverse transcription-PCR analysis. As2O3 did not cause cellular toxicity at this concentration, as revealed by an MTS [3-(4,5-dimethylthiozol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] assay. A combination of AS2O3 and alpha interferon exerted synergistic effects against HCV, as revealed by a multiple linear logistic model and isobologram analysis. Furthermore, in an alternative HCV antiviral system that may recapitulate additional steps involved in HCV infection and replication, AS2O3 at 0.3 μM totally abolished the HCV signal, whereas alpha interferon at a high dose (5,000 IU/ml) only partially suppressed the HCV signal. The study highlights the indications for use of a novel class of anti-HCV agent. Further elucidation of the exact antiviral mechanism of AS2O3 may lead to the development of agents with potent activities against HCV or related viruses.

UR - http://www.scopus.com/inward/record.url?scp=3343022576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3343022576&partnerID=8YFLogxK

U2 - 10.1128/AAC.48.8.2876-2882.2004

DO - 10.1128/AAC.48.8.2876-2882.2004

M3 - Article

VL - 48

SP - 2876

EP - 2882

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -